Correspondence 0001104659-24-058009 from LEAP THERAPEUTICS, INC. (LPTX) (CIK 0001509745) (CYPH)

LEAP THERAPEUTICS, INC. (LPTX) (CIK 0001509745)
Date: May 7, 2024 · CIK: 0001509745 · Accession: 0001104659-24-058009

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-278015

Date

May 7, 2024

Author

Not clearly detected

Form

CORRESP

Company

LEAP THERAPEUTICS, INC. (LPTX) (CIK 0001509745)

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Leap Therapeutics, Inc. — Registration Statement on Form S-3 (File No. 333-278015) (the “Registration Statement”)

Dear Ms. Gama:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Leap Therapeutics, Inc. hereby requests acceleration of the effective date of the Registration Statement so that the Registration Statement becomes effective at 4:05 p.m., Eastern Time, on May 9, 2024, or as soon as practicable thereafter.

Please contact Julio E. Vega of Morgan, Lewis & Bockius LLP at +1.617.951.8901 with any questions you may have concerning this request. In addition, please notify Julio E. Vega when this request for acceleration has been granted.

LEAP THERAPEUTICS, INC.

By: /s/ Douglas E. Onsi

Name: Douglas E. Onsi

Title: Chief Executive Officer, Chief Financial Officer and President

cc: Julio E. Vega (Morgan, Lewis & Bockius LLP)

Show Raw Text

CORRESP
1
filename1.htm

Leap Therapeutics, Inc.

47 Thorndike Street, Suite B1-1

Cambridge, MA 02141

May 7, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, D.C. 20549

Attention: Doris Stacey Gama

    Re:
    Leap Therapeutics, Inc. — Registration Statement on Form S-3

(File No. 333-278015) (the
 “Registration Statement”)

Dear Ms. Gama:

Pursuant to Rule 461 under the Securities Act of 1933, as amended,
Leap Therapeutics, Inc. hereby requests acceleration of the effective date of the Registration Statement so that the Registration
Statement becomes effective at 4:05 p.m., Eastern Time, on May 9, 2024, or as soon as practicable thereafter.

Please contact Julio E. Vega of Morgan, Lewis & Bockius LLP
at +1.617.951.8901 with any questions you may have concerning this request. In addition, please notify Julio E. Vega when this request
for acceleration has been granted.

    LEAP THERAPEUTICS, INC.

    By:
    /s/ Douglas E. Onsi

    Name:
    Douglas E. Onsi

    Title:
    Chief Executive Officer, Chief Financial Officer and
President

    cc:
    Julio E. Vega
(Morgan, Lewis & Bockius LLP)

SecProbe.io